Study Complete
Sponsor ID
20120348
Study to assess in-home use of evolocumab (AMG 145) using a prefilled syringe or a prefilled autoinjector/pen
Study Details
The primary objective of this study was to assess users’ ability to administer a full dose of evolocumab in home-use using either a pre-filled syringe or autoinjector/pen.
Protocol Summary
Primary Outcome Measures
Combination of subject reported outcomes across two attempted full-dose administrations of evolocumab (AMG 145)
Timeframe: 4 weeks
Secondary Outcome Measures
Percent change from baseline in LDL-C at week 6
Timeframe: 6 Weeks
Study Documents
Study Synopsis
Available Language(s): English
Locations
Location
Research Site
Lansdale, PA, United States, 19446
Status
Recruiting
Location
Research Site
Manlius, NY, United States, 13104
Status
Recruiting
Location
Research Site
Miami, FL, United States, 33173
Status
Recruiting
Location
Research Site
Pointe-Claire, QC, Canada, H9R 3J1
Status
Recruiting
Location
Research Site
Port Charlotte, FL, United States, 33952
Status
Recruiting
Location
Research Site
Atlanta, GA, United States, 30342
Status
Recruiting
Showing {first} - {last} of {total} Results